The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...